America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

burger_pills.jpg

Part II.  What Do We Get for All That Money?  A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic;  Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;

Continue reading →

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known. Continue reading →

Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM

FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Continue reading →

Public Servant or Private Marketer? NIH Seeks Inquiry of Alzheimer’s researcher conflicts of interest

NIH: Public Servant or Private Marketer? NIH Seeks Outside Inquiry of Alzheimer’s researcher conflicts of interest – LAT Mon, 31 Jan 2005 A year after the Los Angeles Times published its first an in-depth investigative report documenting in detail evidence of major . . . Continue reading →